Lund Arthritis Research Group (LARG)
1 – 10 of 125
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Predictors of unacceptable pain and the impact of sociodemographic factors and comorbidities—results from a large, nationwide cohort of early rheumatoid arthritis
(2026) In Annals of the Rheumatic Diseases
- Contribution to journal › Article
-
Mark
Impaired cellular immune responses to herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
- Contribution to journal › Article
-
Mark
Exploring the Gap Between Clinical Trials and Real-World Practice in Psoriatic Arthritis
(2026) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
Synovial fluid potentiates local fibroblasts to drive monocyte activation in juvenile idiopathic arthritis
- Contribution to journal › Article
-
Mark
Axial spondyloarthritis patients with comorbid fibromyalgia feel worse, work less and more often try multiple biological therapies : results from a population-based, cross-sectional study investigating the discriminative capacity of pressure algometry
- Contribution to journal › Article
-
Mark
Patients' experiences of managing lifestyle habits following a rheumatoid arthritis diagnosis
- Contribution to journal › Article
- 2025
-
Mark
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Contribution to journal › Scientific review
-
Mark
Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors
- Contribution to journal › Article
-
Mark
Known and less well-known comorbidities in axial spondyloarthritis : what are we overlooking? Results from the SPARTAKUS cohort
- Contribution to journal › Article
-
Mark
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
- Contribution to journal › Article
